BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27688088)

  • 1. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
    Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
    Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
    Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
    Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.
    Kaira K; Murakami H; Serizawa M; Koh Y; Abe M; Ohde Y; Takahashi T; Kondo H; Nakajima T; Yamamoto N
    Virchows Arch; 2011 May; 458(5):615-20. PubMed ID: 21253760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
    Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
    Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
    Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
    Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of proteasome subunit β5t in thymic epithelial tumors.
    Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
    Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
    Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
    Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
    Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
    J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
    Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
    Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
    Nonaka D; Henley JD; Chiriboga L; Yee H
    Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas.
    Roden AC; Yi ES; Jenkins SM; Donovan JL; Cassivi SD; Garces YI; Marks RS; Aubry MC
    Hum Pathol; 2015 Jan; 46(1):17-25. PubMed ID: 25455993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
    Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
    Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
    Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation of amplification of chromosome 1 with histologic typing of thymic epithelial tumors].
    Ma YQ; Zhang C; Cui WL; Gulinaer A; Zhang W; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):820-4. PubMed ID: 22336207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.
    Marx A; Ströbel P; Badve SS; Chalabreysse L; Chan JK; Chen G; de Leval L; Detterbeck F; Girard N; Huang J; Kurrer MO; Lauriola L; Marino M; Matsuno Y; Molina TJ; Mukai K; Nicholson AG; Nonaka D; Rieker R; Rosai J; Ruffini E; Travis WD
    J Thorac Oncol; 2014 May; 9(5):596-611. PubMed ID: 24722150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China.
    Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN
    Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cathepsins V and S in thymic epithelial tumors.
    Kiuchi S; Tomaru U; Ishizu A; Imagawa M; Kiuchi T; Iwasaki S; Suzuki A; Otsuka N; Deguchi T; Shimizu T; Marukawa K; Matsuno Y; Kasahara M
    Hum Pathol; 2017 Feb; 60():66-74. PubMed ID: 27771373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy.
    Wang H; Sima CS; Beasley MB; Illei P; Saqi A; Nonaka D; Geisinger KR; Huang J; Moreira AL
    Arch Pathol Lab Med; 2014 May; 138(5):658-63. PubMed ID: 24786123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumor doubling time is a useful parameter for predicting the histological type of thymic epithelial tumors.
    Fukumoto K; Fukui T; Kawaguchi K; Nakamura S; Hakiri S; Ozeki N; Mori S; Goto M; Hashimoto K; Tateyama H; Yokoi K
    Surg Today; 2019 Aug; 49(8):656-660. PubMed ID: 31134370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.